<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28984/keynote-48-trial-882-patients-were-enrolled-in-under-2-years-primary-endpoint-is-overall-survival-pfs?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Y...

Name: KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Y...
Uploaded: 2019-06-04T07:36:55
Duration: 3 min 44 s
Description: Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary Endpoint Is Overall Survival & PFS.

KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary Endpoint Is Overall Survival & PFS

00:03:44

Annual Meeting

3 years 75 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28984/keynote-48-trial-882-patients-were-enrolled-in-under-2-years-primary-endpoint-is-overall-survival-pfs?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28984/keynote-48-trial-882-patients-were-enrolled-in-under-2-years-primary-endpoint-is-overall-survival-pfs?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28984/keynote-48-trial-882-patients-were-enrolled-in-under-2-years-primary-endpoint-is-overall-survival-pfs?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28984?channelName=AnnualCancerMeeting"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190604193655_dcd0/video_190604193655_dcd0.jpg?cache=15669162511678829655">KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary Endpoint Is Overall Survival & PFS</a>

Link (BBCode):

[url=https://oncologytube.com/v/28984?channelName=AnnualCancerMeeting][img]https://oncologytubecom.cdn.ypt.me/videos/video_190604193655_dcd0/video_190604193655_dcd0.jpg?cache=15669162511678829655[/img]KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary Endpoint Is Overall Survival & PFS[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Head and Neck

Description:

Danny Rischin MD Of Peter MacCallum Cancer Centre Discusses KEYNOTE-48 Trial: 882 Patients Were Enrolled In Under 2 Years, Primary Endpoint Is Overall Survival & PFS.